Search Videos and More
Symposium
Breast Cancer Breakthroughs: ESMO 2025 Highlights
Experts in Dana-Farber’s Breast Oncology Center discuss highlights in breast cancer research innovation presented at ESMO25 in Berlin, Germany, including what the data means, how it can be used in clinic, and what’s next in the field of breast cancer research.
News
Dr. Mariella Filbin Receives 2026 Emerging Leader Award from The Mark Foundation
he Mark Foundation for Cancer Research has named Dr. Mariella Filbin, Research Co-Director of the Pediatric Neuro-Oncology Program at Dana-Farber Cancer Institute, the recipient of the 2026 Emerging Leader Award, recognizing her innovative work to advance treatment options for aggressive childhood brain tumors.
News
Seeing Is Believing
How Technicolor Images of Tumor Samples Are Changing Cancer Research
News
Dana-Farber Researchers Discover How Major Nuclear Protein Complexes Control Specialized Gene Regulation in Cancer and Beyond
The SWI/SNF Ig-Fold for Transcription Factor Interactions or ‘SWIFT’ domain on mSWI/SNF chromatin remodeling complexes engage proteins called transcription factors (TFs) to target specialized genes along human DNA—often cancer-promoting genes—flagging SWIFT-TF interactions as promising new therapeutic targets.
News
Dana-Farber Research News 01.01.2026
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from December 1 - 15.
News
Twenty-Five Years of Progress in Cancer
As we close out the first quarter of the twenty-first century, it isn’t hard to notice how much the world has changed since the year 2000. Smartphones. Social media. Artificial intelligence.
News
Dana-Farber Cancer Institute and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center recognized for exceptional outcomes in donor stem cell transplants
Dana-Farber Cancer Institute’s adult stem cell transplant program and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center’s pediatric stem cell transplant program have once again received exceptional ratings from the Center for International Blood & Marrow Transplant Research (CIBMTR), earning a +1 performance score, the highest possible designation, on their annual center-specific survival reports.
Document
Tip Sheet: Medication-Related Osteonecrosis of the Jaw
The Breast Oncology Center developed this reference for providers caring for patients with medication-related osteonecrosis of the jaw in November 2025.
News
Dana-Farber Research Supports FDA Approval of T-DXd Plus Pertuzumab for First-Line Treatment of HER2+ Metastatic Breast Cancer
The U.S. Food and Drug Administration (FDA) has approved trastuzumab deruxtecan (T-DXd) in combination with pertuzumab for first-line treatment of metastatic HER2-positive breast cancer.
News
Dana-Farber Research News 12.15.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from November 16 - 30.
News
Mobile Health Tool Helps Improve Quality of Life For Young Breast Cancer Survivors
dolescent and young adult breast cancer survivors who used a novel mobile health (mHealth) intervention to self-manage post-treatment symptoms and concerns were able to improve their quality of life and reduce the burden of common symptoms compared to patients who received usual care, according to results from a new clinical trial being reported at the 2025 San Antonio Breast Cancer Symposium (SABCS).
News
Dana-Farber Study Highlights the Need for Faster, More Accurate Diagnosis of Rare Cancer
A new study from Dana-Farber Cancer Institute finds that patients with NUT carcinoma (NC), an aggressive squamous cell lung or head and neck cancer, often face delays in diagnosis—delays that can prevent them from receiving the right treatment or joining clinical trials.